IMMUNITYBIO, INC. Income (Loss) from Continuing Operations before Income Taxes, Domestic
IMMUNITYBIO, INC. (IBRX) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$348.39 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-23.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-02-23
- IMMUNITYBIO, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$348.39M.
- IMMUNITYBIO, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$410.46M.
- IMMUNITYBIO, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$581.14M.
- IMMUNITYBIO, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was -$413.65M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month as first filed |
|---|---|---|
| 2025-12-31 | -$348.39M 10-K · filed 2026-02-23 | |
| 2024-12-31 | -$410.46M 10-K · filed 2026-02-23 | |
| 2023-12-31 | -$581.14M 10-K · filed 2026-02-23 | |
| 2022-12-31 | -$413.65M 10-K · filed 2025-03-03 | |
| 2021-12-31 | -$347.23M 10-K · filed 2024-03-19 | |
| 2020-12-31 | -$223.52M 10-K · filed 2023-03-01 | -$92.41M 10-K · filed 2021-03-04 |
| 2019-12-31 | -$159.09M 10-K · filed 2022-03-01 | -$65.29M 10-K · filed 2020-03-25 |
| 2018-12-31 | -$94.42M 10-K · filed 2021-03-04 | |
| 2017-12-31 | -$94.73M 10-K · filed 2020-03-25 | |
| 2016-12-31 | -$118.74M 10-K · filed 2019-03-13 | |
| 2015-12-31 | -$235.75M 10-K · filed 2018-03-12 | |
| 2014-12-31 | -$6.18M 10-K · filed 2017-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |